ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lilly, Boehringer Partner In Diabetes

by Ann M. Thayer
January 17, 2011 | APPEARED IN VOLUME 89, ISSUE 3

Eli Lilly & Co. and Boehringer Ingelheim will jointly develop a portfolio of diabetes compounds that are in or nearing late-stage development. Lilly will pay $390 million up front to Boehringer Ingelheim, which could also receive up to $820 million in milestone payments related to two oral diabetes agents it will contribute to the alliance. For its two insulin analogs, Lilly could gain $650 million in milestones. If Boehringer chooses to develop Lilly’s anti-TGF-β monoclonal antibody, Lilly would be eligible for up to $525 million more in potential payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment